iBio, Inc., a Texas-based biotechnology company, is making strides in the development and manufacturing of biopharmaceuticals as well as vaccine and therapeutic candidates for a variety of diseases. The company, which operates in two segments, Biopharmaceuticals and Bioprocessing, offers contract development and manufacturing services to third-party customers and collaborators across the United States. iBio's lead anti-fibrotic candidate, IBIO-100, is currently in development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. Additionally, iBio is working on vaccine candidates, including IBIO-202 for the prevention of severe acute respiratory syndrome coronavirus 2 and IBIO-400 for the treatment of classical swine fever. The company is also developing recombinant proteins for third parties and provides process development, manufacturing, and bio analytic services. iBio, Inc. has license agreements with esteemed institutions such as the University of Pittsburgh and The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals. The company also has a license agreement with the University of Natural Resources and Life Sciences, Vienna and a collaboration agreement with RubrYc. With such collaborations and expertise, iBio is poised to make an impact in the biotechnology industry.